The scale of unmet need is staggering. In the United States, more than 103,000 patients sit on organ waiting lists and roughly 17 die each day before a suitable graft arrives. Europe performs around 34,000 transplants annually while approximately 60,000 patients wait. The gap widens dramatically in emerging economies: China performs some 20,000 to 25,000 transplants a year against a deceased-donor rate below four per million population, while India carries out only about 13,500 kidney transplants for roughly 100,000 patients who need one each year. Pigs, with their physiological similarity to humans, short gestation times, large litters, and amenability to genome editing, are the leading candidate to close this gap, but only if production can be scaled to match demand.

Modern donor pigs are biological platforms of remarkable complexity. The leading animals carry knockouts of the GGTA1, CMAH, and B4GALNT2 genes, which eliminate the major xenoantigens αGal, Neu5Gc, and Sd(a) that trigger hyperacute rejection, plus additional human transgenes that temper immune and coagulation incompatibilities. The donor pig used in the first clinical heart xenotransplantation carried ten genetic modifications. Producing such animals at clinical scale relies on somatic cell nuclear transfer, embryo transfer, artificial insemination, and cryopreservation, all while maintaining precise genotypes and strict microbiological standards. The authors model output with a formula combining litters per sow, live-born piglets, pre-weaning and production survival, the proportion retaining designated pathogen-free qualification, and the proportion meeting genetic and organ-specific donor criteria, a reminder that herd mathematics, not just molecular biology, will determine whether organs reach patients.

The arithmetic is sobering. Assuming two transplantable kidneys per pig, Europe would need a theoretical minimum of 10,000 to 12,500 donor pigs annually just to replace current kidney transplant activity, and realistic estimates that account for donor exclusion, organ discard, transport losses, and reserve capacity push the figure to 15,000 to 20,000. The United States would require roughly 18,000 to 20,000. Asia dwarfs both: meeting even a fraction of projected kidney demand in China could require 75,000 to 150,000 donor pigs a year, with India needing 50,000 to 75,000. A facility producing 5,000 clinically eligible donor pigs annually would need around 250 to 300 breeding sows and a total herd of 3,000 to 5,000 animals. Replacing Germany’s kidney transplant activity alone would demand one dedicated large-scale facility; Europe or the United States would likely need three to five production centers.

Biosafety forms the second pillar of the logistics challenge. Donor pigs must be raised in designated pathogen-free facilities operating like high-containment biomedical production plants, with positive-pressure barrier housing, HEPA-filtered ventilation, sterilized feed and water, restricted personnel access, and continuous environmental monitoring. The DPF pathogen panel is defined by intended clinical use rather than a fixed list, and surveillance targets porcine cytomegalovirus, porcine reproductive and respiratory syndrome virus, hepatitis E virus, circoviruses, influenza viruses, and porcine endogenous retroviruses. The stakes were made vivid by the first clinical pig-heart transplant, in which PCMV was detected in the donor organ and likely contributed to graft dysfunction; preclinical studies in non-human primates show the virus markedly shortens xenograft survival. Porcine endogenous retroviruses pose a distinct problem because they are woven into the pig genome, though CRISPR-Cas9 approaches have now inactivated multiple PERV sequences in donor animals, and no clinical transmission has ever been documented.

The review also stresses reverse logistics, an aspect rarely discussed. Biosecure networks need predefined procedures for isolating animals after suspected pathogen exposure, movement restrictions during outbreaks, safe disposal of culled donor animals, and validated containment and decontamination pathways for biological samples and medical waste. Recipients themselves become part of the surveillance architecture: regulators in both the United States and Europe recommend lifelong monitoring, periodic virological screening, donor tissue archiving, and participation in national registries. Every xenograft must be traceable back to its donor animal, breeding facility, genetic background, and screening results, documentation that resembles pharmaceutical batch records more than transplant charts. Paradoxically, the authors note that because viruses such as HIV-1, human cytomegalovirus, Epstein-Barr virus, and even rabies have been transmitted through human allotransplants, carefully screened xenotransplantation may ultimately prove safer on infectious-disease grounds than conventional transplantation.

The most transformative lever, however, may be machine perfusion. Static cold storage imposes hard limits: hearts tolerate only four to six hours of cold ischemia, lungs six to eight, livers eight to twelve, and kidneys 24 to 36. Hypothermic oxygenated perfusion keeps organs at low metabolic demand while delivering controlled oxygen, supporting mitochondrial recovery, and clinical studies in kidney transplantation show reduced delayed graft function. Normothermic machine perfusion goes further, keeping organs metabolically active so that vascular resistance, oxygen consumption, urine production, and bile secretion can be monitored in real time, turning preservation from passive storage into active quality assessment. Preservation periods exceeding 24 hours have already been reported for several organ types, and experimental work has successfully perfused gene-modified porcine kidneys, livers, and lungs on clinically approved systems. Extended windows could let centrally produced organs be distributed across entire countries or continents.

Distribution architecture is the final piece. Centralized mega-facilities offer standardized quality control and economies of scale but create single points of failure and long transport routes. Fully decentralized facilities near transplant centers shorten distances but duplicate expensive infrastructure and surveillance systems. The authors favor a hybrid regional hub-and-spoke model, in which strategically located donor facilities supply perfusion hubs that assess, optimize, and redistribute organs, a concept already demonstrated by collaborative perfusion hubs evaluating αGal-knockout porcine livers and lungs under normothermic conditions. Europe’s existing cross-border infrastructure, notably Eurotransplant, could provide the framework for such networks. Asia faces different constraints, including vast distances, uneven cold-chain and air-cargo capacity, and heterogeneous national regulations, which may favor regionally clustered production rather than centralized megafacilities.

Economics and public acceptance will shape demand as much as medical need. Dialysis costs frequently exceed 60,000 to 100,000 euros per patient annually in Europe and around 90,000 dollars in the United States, and registry analyses show kidney transplantation becomes cheaper than dialysis within roughly three years, making scalable xenotransplantation potentially cost-saving for chronic kidney disease. Yet the acquisition cost of a gene-edited pig organ remains essentially unquantifiable until production reaches clinical scale, and early procedures will be expensive. A survey in China found that although most respondents had heard of xenotransplantation, only 4.9 percent considered themselves very familiar with it and just 36.7 percent would definitely accept a life-saving xenograft, with concerns centering on safety, outcomes, and cost. Looking further ahead, advances in vitrification and nanowarming have enabled rat kidneys to be cryopreserved for up to 100 days and successfully transplanted, and liter-scale vitrification has been demonstrated in porcine livers, hinting at future organ banks that would fully decouple procurement from surgery. If the supply chain the authors envision can be built, transplantation could evolve from a scarcity-driven emergency discipline into a predictable, scalable therapeutic platform, one planned pig herd, perfusion hub, and delivery route at a time.

Subject of Research: Logistics and supply-chain requirements for clinical pig-to-human xenotransplantation

Article Title: Logistics of clinical xenotransplantation: from donor pig production to global organ distribution

Article References: Fischer, K., Denner, J., Tönjes, R. R., Felgendreff, P., & Rahmel, A. (2026). Logistics of clinical xenotransplantation: from donor pig production to global organ distribution. Transplant International, 39, Article 17326. https://doi.org/10.3389/ti.2026.17326

Image Credits: AI Generated

DOI: 10.3389/ti.2026.17326

Keywords: xenotransplantation, donor pigs, gene editing, organ shortage, machine perfusion, biosafety, organ preservation, organ distribution, porcine endogenous retrovirus, regulation, dialysis costs, public acceptance